Results 11 to 20 of about 5,389 (186)

A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study

Cancer Medicine
Background Colorectal cancer (CRC) is a major health burden globally and in China, where 3%–5% of cases involve the BRAFV600E mutation, which is associated with aggressive disease and therefore a poor prognosis.
Wang Xicheng, Deng Yanhong, Zhang Yanqiao, Liu Tianshu, Yuan Xianglin, Yang Jianwei, Zhang Tao, Zang Aimin, Liu Yu, Huang Li, Ye Feng, Zong Hong, Ba Yi, Klauck Isabelle, Vedovato Jean‐Claude, Groc Mélanie, Guo Angela, Li Jian, Shen Lin   +18 more
doaj   +2 more sources

Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols [PDF]

Dermatology Reports
Only three combinations of BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) targeted therapies are marketed for the treatment of BRAF-mutated metastatic melanoma. The use of these combinations can be limited by the occurrence of severe adverse events (AEs)
François Pélouard, Valérie Chedru-Legros, Catherine Nganoa, Anne Dompmartin, Jean-Matthieu L'Orphelin   +4 more
doaj   +2 more sources

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer [PDF]

Cancer Immunology, Immunotherapy
BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials.
Eunyoung Tak, Hye-In An, Amy Sinyoung Lee, Kyuyoung Han, Jiwan Choi, Hyung-don Kim, Yong Sang Hong, Sun Young Kim, Eun Kyung Choi, Jeong Eun Kim, Tae Won Kim   +10 more
doaj   +2 more sources

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer. [PDF]

Clin Pharmacol Ther
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Piscitelli J, Reddy MB, Wollenberg L, Del Frari L, Gong J, Matschke K, Williams JH.   +6 more
europepmc   +2 more sources

Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF^V600-mutant melanoma in Spain: the BECARE (GEM-2002) trial. [PDF]

Front Oncol
Immune checkpoint inhibitors; Melanoma; MutationInhibidores de puntos de control inmunitario; Melanoma; MutaciónInhibidors de punts de control immunitari; Melanoma; MutacióPurpose: Combined BRAF/MEK inhibition with encorafenib (E) plus binimetinib (B ...
Soria A, Sanchez Mauriño P, Serrano Domingo JJ, García Galindo R, Sequero S, Gutiérrez Sanz L, Crespo G, Díaz-Beveridge R, Puértolas T, López P, Fra Rodríguez J, López Castro R, Aguayo C, Valdivia J, Cunquero-Tomás AJ, Benítez G, Ayala de Miguel P, Espinosa E, Muñoz-Couselo E, Campos B, García Sánchez L, Cerezuela-Fuentes P.   +21 more
europepmc   +3 more sources

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo

Pharmaceutics, 2022
Encorafenib (LGX818, trade name Braftovi), a novel BRAF inhibitor, has been approved for the treatment of melanoma and colorectal cancer. In the present work, we evaluated encorafenib’s possible antagonistic effects on the pharmacokinetic mechanisms of ...
Yu Zhang, Dimitrios Vagiannis, Youssif Budagaga, Ziba Sabet, Ivo Hanke, Tomáš Rozkoš, Jakub Hofman   +6 more
doaj   +1 more source

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

BMJ Open, 2022
Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor ...
David Malka, Philippe Laramée, Mondher Toumi, Jean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, Dan Howard, Andy Buckland, Marine Sivignon, Emilie Clay, Emmanuelle Samalin   +10 more
doaj   +1 more source

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

Clinical and Translational Science, 2023
Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer.
Erik Hahn, Renae Chavira, Lance Wollenberg, Weiwei Tan, Micaela B. Reddy   +4 more
doaj   +1 more source

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia

Фармакоэкономика, 2023
Objective: to perform a cost-effectiveness analysis of using encorafenib and binimetinib combination in the first-line therapy for metastatic or unresectable BRAF V600-mutated melanoma in the Russian Federation. Material and methods.
N. A. Avxentyev, Yu. V. Makarova
doaj   +1 more source

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects

Pharmacology Research & Perspectives, 2023
Encorafenib is a novel kinase inhibitor of BRAF V600E as well as wild‐type BRAF and CRAF and has received approval, in combination with binimetinib, to treat BRAF V600E or V600K mutation‐positive unresectable or metastatic melanoma or in combination with
Lance Wollenberg, Erik Hahn, Jason Williams, Kevin Litwiler   +3 more
doaj   +1 more source